Tumor markers can help monitor ROS1, ALK, EGFR, and KRAS lung cancer patients


Tumor markers (certain molecules in the blood of cancer patients) can provide a useful “early warning” for cancer progression in patients whose lung cancer has alterations in ROS1, ALK, EGFR and KRAS genes. An analysis of data from 142 patients reviewed four tumor markers (CEA, CA125, CA19.9 and CA27.29) and found at least one tumor … Continue reading Tumor markers can help monitor ROS1, ALK, EGFR, and KRAS lung cancer patients

Announcing a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer


FOR IMMEDIATE RELEASE August 15, 2017 CONTACT: Samantha Cummis Addario Lung Cancer Medical Institute 650-598-2857 Samantha@LungCancerFoundation.org Susan Foreman Champions Oncology, Inc. 410-369-0365 SForeman@ChampionsOncology.com The Addario Lung Cancer Medical Institute, Champions Oncology and Motivated Patients Announce a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer SAN CARLOS, Calif. And Hackensack, … Continue reading Announcing a Research Collaboration and Launch of a Patient Driven Clinical Study in ROS1 Positive Cancer

TPX-0005 (in trials for ROS1+ cancers) receives orphan drug designation


A TP Therapeutics, Inc. drug designated TPX-0005 received FDA Orphan Drug Designation on June 27, 2017.  The first patient enrolled in March 2017 in the TPX-0005 Phase 1 clinical trial for advanced solid tumors with ROS1, ALK, and NTRK rearrangements. Here is the clinical trial listing on clinicaltrials.gov: NCT03093116:  A Study of TPX-0005 in Patients … Continue reading TPX-0005 (in trials for ROS1+ cancers) receives orphan drug designation